Search Medical Condition
Please enter condition
Please choose location from dropdown

Masstricht, Netherlands Clinical Trials

A listing of Masstricht, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (308) clinical trials

Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System

To investigate fall risk objectively, fall related movement characteristics (based on gait and balance) and the ability to compensate for near falls are analyzed in younger and older (>60y) subjects under standardized laboratory conditions. Four tests will be performed to link specific movement parameters, balance performance and the ability to ...

Phase

0.0 miles

Learn More »

Development of an Acceleration Based Fall Risk Detector

A first step to field measurement with target group is the measurement of elderly with a certain fall risk in a simple field condition like a nursing home. First fall risk is assessed in elderly using the Tinetti scale (score between 19-24) which is the gold standard for fall risk ...

Phase N/A

0.0 miles

Learn More »

Maastricht IBS Cohort

Aim of the present study is to set up a large cohort of IBS patients in order to identify different disease characteristics as well as aetiological and pathophysiological factors in (sub)groups of patients with this heterogeneous disorder. Various phenotypical and genotypical markers will be evaluated. For this purpose, blood and ...

Phase N/A

0.0 miles

Learn More »

Predictive Value for Stroke

Patients with a moderate to severe carotid atherosclerotic plaque are at risk for stroke and this risk increases with increasing degree of stenosis. It has been shown that carotid endarterectomy in symptomatic patients with a carotid artery stenosis of 70-99% is highly beneficial. However, the beneficial effect of surgery in ...

Phase N/A

0.0 miles

Learn More »

European Multicenter Randomized Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent

Occlusive coronary artery disease is predominantly caused by coronary atherosclerosis, a pathologic vascular condition characterized by abnormal lipid and fibrous tissue accumulation in the vessel wall. This condition may be accompanied by degenerative changes and/or calcification leading to stenosis (narrowing) of the luminal channel. Percutaneous Transluminal Coronary Angioplasty (PTCA) is ...

Phase

0.0 miles

Learn More »

Micro- and Macrovascular Adaptations in Patients With Peripheral Arterial Disease During Supervised Exercise Therapy

Given that previous studies demonstrated the feasibility of the required MRI techniques, we propose to study the macro- and microvascular adaptations in PAOD patients undergoing supervised exercise therapy. It is expected to provide valuable insights into the contribution of each vascular mechanism to the rehabilitation and to identify which vascular ...

Phase N/A

0.0 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »

The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome

It is necessary to state whether correlations between objective findings and subjective perception of symptoms exist, and whether the patient's 'everyday' symptoms are reproduced during objective studies, when the results are reported. The principle aim of urodynamics is to reproduce a patient's symptoms and to provide a patho physiological explanation ...

Phase N/A

0.0 miles

Learn More »

Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+ HER2-negative aBC With PIK3CA Mutations Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant

Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrant

Phase

0.0 miles

Learn More »